SCHEMBL6780805

SCHEMBL6780805

CCOc1ccc(C(=O)N(Cc2ccccc2-c2ccccc2)c2ccncc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ PTGES O14684 1/20 0.45
▸ ALOX5 P09917 1/20 0.45
▸ LTB4R2 Q9NPC1 1/20 0.45
▸ FFAR1 O14842 1/20 0.44
▸ FFAR4 Q5NUL3 1/20 0.44
▸ PDE10A Q9Y233 3/20 0.44
▸ MAPT P10636 2/20 0.43
▸ LMNA P02545 3/20 0.43
▸ MAPK14 Q16539 1/20 0.41
▸ TP53 P04637 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778429 0.83 MAPT (0.50) L3MBTL1LTB4R2MAPTLMNA
SCHEMBL6773967 0.83 OXTR (0.53) L3MBTL1PTGESALOX5FFAR1FFAR4
SCHEMBL6778364 0.81 PTGES (0.56) KMT2APTGESALOX5LTB4R2MAPT
SCHEMBL6785255 0.78 LMNA (0.51) KMT2ANPSR1L3MBTL1FFAR1FFAR4
SCHEMBL6775891 0.76 PDK1 (0.47) KMT2AL3MBTL1LTB4R2MAPTPOLB
SCHEMBL6783999 0.74 PTGER1 (0.47) PTGESALOX5LTB4R2HTT
SCHEMBL6785514 0.74 LTB4R2 (0.46) KMT2ALTB4R2MEN1
SCHEMBL6778305 0.74 LTB4R2 (0.52) KMT2ANPSR1L3MBTL1LTB4R2FFAR1
SCHEMBL6781088 0.72 ALDH1A1 (0.45) L3MBTL1LTB4R2MAPTCYP3A4CYP2C9
SCHEMBL6775116 0.72 MAPKAPK2 (0.41) KMT2ALTB4R2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US claimed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US claimed
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT KMT2A 1440/4885NPSR1 3567/4885L3MBTL1 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback